{"id":"W1831380443","doi":"10.3747/co.2007.132","title":"Phase II Testing of Sunitinib: The National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185","year":2007,"lang":"en","type":"article","venue":"Current Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre; Queen's University; Cancer Care Ontario; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Sunitinib; Clinical trial; Bevacizumab; Vascular endothelial growth factor; Oncology; Angiogenesis; Internal medicine; PDGFRA; Tyrosine-kinase inhibitor; Cancer research; Cancer; Chemotherapy; VEGF receptors; Stromal cell; GiST","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002638819,0.001179504,0.001506339,0.0004833918,0.001031558,0.001086895,0.001034743,0.002103658,0.00538312],"category_scores_gemma":[0.001422202,0.0005386735,0.000971646,0.000407295,0.000913347,0.0004358337,0.0003536494,0.002629687,0.001162185],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003608906,"about_ca_system_score_gemma":0.008711783,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02710402,"about_ca_topic_score_gemma":0.08935452,"domain_scores_codex":[0.9991604,0.0003031697,0.00003149272,0.00009354518,0.0001973325,0.000214026],"domain_scores_gemma":[0.9988482,0.00009379695,0.0001322186,0.00007480384,0.0002149574,0.0006360837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4682258,0.05414891,0.01419985,0.001328621,0.001670601,0.0009553457,0.0006282812,0.004681902,0.05735449,0.002598965,0.1224846,0.2717226],"study_design_scores_gemma":[0.5800991,0.273429,0.03775556,0.0001082946,0.0007235781,0.0008223858,0.0001580392,0.003160202,0.01132604,0.0008011942,0.09152136,0.00009533799],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8706304,0.01297117,0.004430857,0.007832979,0.001396459,0.03984309,0.01794414,0.0006026893,0.04434818],"genre_scores_gemma":[0.9084359,0.005809249,0.007718195,0.005530636,0.0004154299,0.01585334,0.01536325,0.0001109573,0.04076301],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.972896,"threshold_uncertainty_score":0.05389249,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.6175286996166528,"score_gpt":0.6092700241267817,"score_spread":0.008258675489871137,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}